Technology Partners

Cambridge University

This ongoing collaboration started in March 2011 with researchers from the University of Cambridge to create a new company, named Phenomica, to pursue a novel application of Phylogica’s Phylomer^® peptides for the discovery of disease-associated targets.

Phenomica, based in Cambridge, UK combines Phylogica’s Phylomer^® libraries with technology from Cambridge to identify vulnerable points in a disease that can be the focus for new drug development.

Press release 2011 (pdf, 98 kB)

Isogenica

This ongoing agreement, which started in February 2011, enables Phylogica to use Isogenica’s CIS display technology to optimize the performance of three of Phylogica’s lead compounds targeting CD40 ligand (CD40L), a key protein involved in many inflammatory diseases. Isogenica’s CIS display technology allows a comprehensive search process to optimize the exact chemical and three dimensional structure required to further enhance the properties of the Phylomer^® peptides, improving drug properties such as affinity, stability and potency.

Press release 2011 (pdf, 36 kB)

Pepscan Therapeutics

This ongoing research collaboration and option agreement was started in May 2011 to evaluate the combination of their complementary peptide technologies for drug discovery. Pepscan is utilising its CLIPS technology will work with Phylogica to optimise novel therapeutic Phylomer drug candidates against CD40-ligand for the treatment of rheumatoid arthritis, autoimmune diseases and inflammatory disorders.

Press release 2011 (pdf, 95 kB)

XL-protein

This ongoing alliance was started in January 2011 to evaluate XL-protein’s PASylation technology for extending the half life of Phylogica’s peptides. The technology utilises a genetic technique to fuse a polymer onto the relevant peptide or protein-based therapeutic, which slows the body’s clearance of the drug and prolongs the therapeutic effect.

Press release 2011 (pdf, 32 kB)